-
AstraZeneca's Imfinzi receives US FDA approval to treat patients with limited─stage small cell lung cancer
06 Dec 2024 04:06 GMT
… extensive-stage small cell lung cancer, underscoring our commitment … portfolio includes leading lung cancer medicines and the … including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi and … improvements for people with lung cancer, including and beyond …
-
US FDA approves AstraZeneca's Tagrisso for patients with unresectable, stage III EGFR─mutated lung cancer
27 Sep 2024 06:10 GMT
… diagnosed with lung cancer globally. Lung cancer is the … Lung cancer is broadly split into NSCLC and small cell lung cancer … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … for people with lung cancer, including and beyond …
-
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
24 Aug 2024 10:55 GMT
… Abbreviations
LC, Lung cancer; NSCLC, Non-small cell lung cancer; BMs, … -1
14. EMA. Iressa Summary of Product Characteristics; … characterization of squamous cell lung cancers. Nature. 2012;489 … positive non-small cell lung cancer. Lung Cancer. 2020;146(1): …
-
EU approves AstraZeneca's Tagrisso with addition of chemotherapy as new 1st─line treatment for patients with EGFR─mutated advanced lung cancer
06 Jul 2024 07:05 GMT
… deaths. Lung cancer is broadly split into NSCLC and small cell lung cancer. Each … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … meaningful improvements for people with lung cancer, including and beyond treatment.
…
-
AstraZeneca's Tagrisso with addition of chemotherapy approved in Japan to treat patients with EGFR─mutated advanced lung cancer
26 Jun 2024 04:54 GMT
… for patients with EGFR-mutated lung cancer either in combination with chemotherapy … deaths. Lung cancer is broadly split into NSCLC and small cell lung cancer. Each … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa …
-
US FDA accepts and granted priority review status to AstraZeneca's sNDA for Tagrisso for patients with unresectable, stage III EGFR─mutated lung cancer
11 Jun 2024 03:54 GMT
… EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy … in EGFR-mutated lung cancer, extending progression-free … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … for people with lung cancer, including and beyond …
-
EMA committee recommends approval of AstraZeneca's Tagrisso with the addition of chemotherapy for patients with EGFR─mutated advanced lung cancer
04 Jun 2024 09:39 GMT
… with EGFR-mutated lung cancer, demonstrating a … Lung cancer is broadly split into NSCLC and small cell lung cancer … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … for people with lung cancer, including and beyond …
-
AstraZeneca : Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K
03 Jun 2024 10:41 GMT
… EGFRm NSCLC.
Notes
Lung cancer
Lung cancer is the leading … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … for people with lung cancer, including and beyond … /lung-cancer-101/types-of-lung-cancer. Accessed …
-
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
27 May 2024 11:17 GMT
… non-small cell lung cancer
Nearly 2.5 million lung cancer cases were diagnosed … innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo … of TROP2 in non‐small lung cancers and its correlation with abnormal …
-
What’s behind a six-fold jump in cure rate of stage 4 lung cancer?
16 May 2024 06:19 GMT
… stage 4 lung cancer, one of the worst types of lung cancer, has … of EGFR-targeted anticancer drugs, Iressa, and the second generation, … enough to shrink their lung cancer mass from for centimeters … and survival rate of lung cancer have increased in combination …
About
© 1995-2024